Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.71 |
| ▸ | MMP1 | P03956 | 7/20 | 0.59 |
| ▸ | MMP2 | P08253 | 4/20 | 0.59 |
| ▸ | MMP3 | P08254 | 4/20 | 0.59 |
| ▸ | MMP9 | P14780 | 5/20 | 0.54 |
| ▸ | MMP13 | P45452 | 5/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823690 | 0.89 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DMMP1 | |
| SCHEMBL6822891 | 0.89 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DMMP1 | |
| SCHEMBL6823167 | 0.89 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DMMP1 | |
| SCHEMBL5702910 | 0.89 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DMMP1 | |
| SCHEMBL6819921 | 0.89 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DMMP1 | |
| SCHEMBL6819940 | 0.89 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DMMP1 | |
| SCHEMBL6819908 | 0.89 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DMMP1 | |
| SCHEMBL5702978 | 0.88 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DMMP1 | |
| SCHEMBL5702892 | 0.88 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DMMP1 | |
| SCHEMBL5702906 | 0.87 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6057369-A | USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-05-02 | — | — | US | claimed |
| EP-0871439-A4 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-07-21 | — | — | EP | claimed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | claimed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | claimed |
| EP-0871439-B1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARMA INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6057369-A | USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0871439-A4 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |